• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

从感染 A 型和 B 型病毒的个体中克隆的 HIV-1 gp140 的记忆 B 细胞抗体。

Memory B cell antibodies to HIV-1 gp140 cloned from individuals infected with clade A and B viruses.

机构信息

Laboratory of Molecular Immunology, The Rockefeller University, New York, New York, United States of America.

出版信息

PLoS One. 2011;6(9):e24078. doi: 10.1371/journal.pone.0024078. Epub 2011 Sep 8.

DOI:10.1371/journal.pone.0024078
PMID:21931643
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3169578/
Abstract

Understanding the antibody response to HIV-1 in humans that show broad neutralizing serologic activity is a crucial step in trying to reproduce such responses by vaccination. Investigating antibodies with cross clade reactivity is particularly important as these antibodies may target conserved epitopes on the HIV envelope gp160 protein. To this end we have used a clade B YU-2 gp140 trimeric antigen and single-cell antibody cloning methods to obtain 189 new anti-gp140 antibodies representing 51 independent B cell clones from the IgG memory B cells of 3 patients infected with HIV-1 clade A or B viruses and exhibiting broad neutralizing serologic activity. Our results support previous findings showing a diverse antibody response to HIV gp140 envelope protein, characterized by differentially expanded B-cell clones producing highly hypermutated antibodies with heterogenous gp140-specificity and neutralizing activity. In addition to their high-affinity binding to the HIV spike, the vast majority of the new anti-gp140 antibodies are also polyreactive. Although none of the new antibodies are as broad or potent as VRC01 or PG9, two clonally-related antibodies isolated from a clade A HIV-1 infected donor, directed against the gp120 variable loop 3, rank in the top 5% of the neutralizers identified in our large collection of 185 unique gp140-specific antibodies in terms of breadth and potency.

摘要

了解对具有广泛中和血清学活性的人类 HIV-1 抗体反应是通过疫苗接种来复制这种反应的关键步骤。研究具有跨谱系反应性的抗体尤其重要,因为这些抗体可能针对 HIV 包膜 gp160 蛋白上的保守表位。为此,我们使用了一株 clade B YU-2 gp140 三聚体抗原和单细胞抗体克隆方法,从 3 名感染 HIV-1 clade A 或 B 病毒且具有广泛中和血清学活性的 IgG 记忆 B 细胞中获得了 189 种新的抗 gp140 抗体,代表 51 个独立的 B 细胞克隆。我们的研究结果支持先前的发现,表明对 HIV gp140 包膜蛋白存在多样化的抗体反应,其特征是不同程度扩增的 B 细胞克隆产生高度超突变的抗体,具有异质性的 gp140 特异性和中和活性。除了与 HIV 刺突的高亲和力结合外,绝大多数新的抗 gp140 抗体也是多反应性的。尽管新抗体没有 VRC01 或 PG9 那么广泛或有效,但从一名感染 clade A HIV-1 的供体中分离出的两种与 clonally-related 的抗体,针对 gp120 可变环 3,在我们的 185 种独特的 gp140 特异性抗体中,在广度和效力方面,排名前 5%。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cbf2/3169578/ff466070cc7d/pone.0024078.g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cbf2/3169578/f24ade51e9dc/pone.0024078.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cbf2/3169578/2da12f2d44ea/pone.0024078.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cbf2/3169578/d0394987230e/pone.0024078.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cbf2/3169578/e318416abb59/pone.0024078.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cbf2/3169578/2637f9afce78/pone.0024078.g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cbf2/3169578/732ba56b7f7a/pone.0024078.g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cbf2/3169578/ff466070cc7d/pone.0024078.g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cbf2/3169578/f24ade51e9dc/pone.0024078.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cbf2/3169578/2da12f2d44ea/pone.0024078.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cbf2/3169578/d0394987230e/pone.0024078.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cbf2/3169578/e318416abb59/pone.0024078.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cbf2/3169578/2637f9afce78/pone.0024078.g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cbf2/3169578/732ba56b7f7a/pone.0024078.g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cbf2/3169578/ff466070cc7d/pone.0024078.g007.jpg

相似文献

1
Memory B cell antibodies to HIV-1 gp140 cloned from individuals infected with clade A and B viruses.从感染 A 型和 B 型病毒的个体中克隆的 HIV-1 gp140 的记忆 B 细胞抗体。
PLoS One. 2011;6(9):e24078. doi: 10.1371/journal.pone.0024078. Epub 2011 Sep 8.
2
Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals.从HIV感染个体的记忆B细胞中分离出的中和抗体具有广泛的多样性。
Nature. 2009 Apr 2;458(7238):636-40. doi: 10.1038/nature07930. Epub 2009 Mar 15.
3
Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop.从一名感染HIV-1 C亚型的精英中和者体内获得的构象表位特异性广泛中和性血浆抗体通过V1环区的突变介导自体病毒逃逸。
J Virol. 2016 Jan 13;90(7):3446-57. doi: 10.1128/JVI.03090-15.
4
Envelope proteins of two HIV-1 clades induced different epitope-specific antibody response.两种 HIV-1 亚型的包膜蛋白诱导了不同的表位特异性抗体反应。
Vaccine. 2018 Mar 14;36(12):1627-1636. doi: 10.1016/j.vaccine.2018.01.081. Epub 2018 Feb 9.
5
Identification and characterization of a new cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody.一种新型交叉反应性1型人类免疫缺陷病毒中和性人单克隆抗体的鉴定与表征
J Virol. 2004 Sep;78(17):9233-42. doi: 10.1128/JVI.78.17.9233-9242.2004.
6
Broad and Potent Neutralizing Antibodies Recognize the Silent Face of the HIV Envelope.广谱且强效的中和抗体识别 HIV 包膜的“沉默面”。
Immunity. 2019 Jun 18;50(6):1513-1529.e9. doi: 10.1016/j.immuni.2019.04.014. Epub 2019 May 21.
7
Engineering, expression, purification, and characterization of stable clade A/B recombinant soluble heterotrimeric gp140 proteins.工程化表达、纯化及稳定 clade A/B 重组可溶性三聚体 gp140 蛋白的鉴定。
J Virol. 2012 Jan;86(1):128-42. doi: 10.1128/JVI.06363-11. Epub 2011 Oct 26.
8
High titer HIV-1 V3-specific antibodies with broad reactivity but low neutralizing potency in acute infection and following vaccination.在急性感染和接种疫苗后,具有广泛反应性但中和效力较低的高滴度HIV-1 V3特异性抗体。
Virology. 2009 May 10;387(2):414-26. doi: 10.1016/j.virol.2009.02.022. Epub 2009 Mar 18.
9
Cross-reactive HIV-1 neutralizing monoclonal antibodies selected by screening of an immune human phage library against an envelope glycoprotein (gp140) isolated from a patient (R2) with broadly HIV-1 neutralizing antibodies.通过筛选免疫人噬菌体文库以对抗从具有广泛HIV-1中和抗体的患者(R2)分离出的包膜糖蛋白(gp140)而选择的交叉反应性HIV-1中和单克隆抗体。
Virology. 2007 Jun 20;363(1):79-90. doi: 10.1016/j.virol.2007.01.015. Epub 2007 Feb 15.
10
Clade C HIV-1 Envelope Vaccination Regimens Differ in Their Ability To Elicit Antibodies with Moderate Neutralization Breadth against Genetically Diverse Tier 2 HIV-1 Envelope Variants.C 型 HIV-1 包膜疫苗方案在诱导具有中度广谱中和能力的抗体方面存在差异,可针对遗传多样性的 2 级 HIV-1 包膜变异体。
J Virol. 2019 Mar 21;93(7). doi: 10.1128/JVI.01846-18. Print 2019 Apr 1.

引用本文的文献

1
Combination immunotherapy induces post-intervention control of HIV.联合免疫疗法可诱导HIV的干预后控制。
Res Sq. 2025 Mar 19:rs.3.rs-6141479. doi: 10.21203/rs.3.rs-6141479/v1.
2
Sustained HIV remission after allogeneic hematopoietic stem cell transplantation with wild-type CCR5 donor cells.使用野生型CCR5供体细胞进行异基因造血干细胞移植后实现持续的HIV缓解。
Nat Med. 2024 Dec;30(12):3544-3554. doi: 10.1038/s41591-024-03277-z. Epub 2024 Sep 2.
3
TMPRSS2 is a functional receptor for human coronavirus HKU1.TMPRSS2 是人类冠状病毒 HKU1 的功能性受体。

本文引用的文献

1
Passive neutralizing antibody controls SHIV viremia and enhances B cell responses in infant macaques.被动中和抗体可控制 SHIV 病毒血症并增强婴儿恒河猴的 B 细胞反应。
Nat Med. 2010 Oct;16(10):1117-9. doi: 10.1038/nm.2233. Epub 2010 Oct 3.
2
Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation.多反应性通过异连接增加抗 HIV 抗体的表观亲和力。
Nature. 2010 Sep 30;467(7315):591-5. doi: 10.1038/nature09385.
3
A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals.
Nature. 2023 Dec;624(7990):207-214. doi: 10.1038/s41586-023-06761-7. Epub 2023 Oct 25.
4
HIV-1 treatment timing shapes the human intestinal memory B-cell repertoire to commensal bacteria.HIV-1 治疗时机塑造了人类肠道记忆 B 细胞对共生菌的反应。
Nat Commun. 2023 Oct 10;14(1):6326. doi: 10.1038/s41467-023-42027-6.
5
Potent human broadly SARS-CoV-2-neutralizing IgA and IgG antibodies effective against Omicron BA.1 and BA.2.强效的人源广谱 SARS-CoV-2 中和性 IgA 和 IgG 抗体可有效对抗奥密克戎 BA.1 和 BA.2。
J Exp Med. 2022 Jul 4;219(7). doi: 10.1084/jem.20220638. Epub 2022 Jun 15.
6
Prolonged viral suppression with anti-HIV-1 antibody therapy.抗 HIV-1 抗体治疗实现病毒长期抑制。
Nature. 2022 Jun;606(7913):368-374. doi: 10.1038/s41586-022-04597-1. Epub 2022 Apr 13.
7
Transient viral exposure drives functionally-coordinated humoral immune responses in HIV-1 post-treatment controllers.一过性病毒暴露驱动 HIV-1 治疗后控制者中功能协调的体液免疫应答。
Nat Commun. 2022 Apr 11;13(1):1944. doi: 10.1038/s41467-022-29511-1.
8
HIV-gp140-Specific Antibodies Generated From Indian Long-Term Non-Progressors Mediate Potent ADCC Activity and Effectively Lyse Reactivated HIV Reservoir.来自印度长期非进展者的 HIV-gp140 特异性抗体可介导有效的 ADCC 活性,并有效裂解再激活的 HIV 储存库。
Front Immunol. 2022 Mar 2;13:844610. doi: 10.3389/fimmu.2022.844610. eCollection 2022.
9
Epitope convergence of broadly HIV-1 neutralizing IgA and IgG antibody lineages in a viremic controller.在一名病毒血症控制者中,广谱 HIV-1 中和 IgA 和 IgG 抗体谱系的表位汇聚。
J Exp Med. 2022 Mar 7;219(3). doi: 10.1084/jem.20212045. Epub 2022 Mar 1.
10
Broadly Neutralizing Antibodies for HIV-1 Prevention.广谱中和抗体在 HIV-1 预防中的应用。
Front Immunol. 2021 Jul 20;12:712122. doi: 10.3389/fimmu.2021.712122. eCollection 2021.
在一些 HIV-1 感染者中,有限数量的抗体特异性可介导广泛而有效的血清中和作用。
PLoS Pathog. 2010 Aug 5;6(8):e1001028. doi: 10.1371/journal.ppat.1001028.
4
Human anti-HIV-neutralizing antibodies frequently target a conserved epitope essential for viral fitness.人体抗 HIV 中和抗体经常针对一个对病毒适应性至关重要的保守表位。
J Exp Med. 2010 Aug 30;207(9):1995-2002. doi: 10.1084/jem.20101176. Epub 2010 Aug 2.
5
Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1.包膜的合理设计鉴定出针对 HIV-1 的广泛中和人源单克隆抗体。
Science. 2010 Aug 13;329(5993):856-61. doi: 10.1126/science.1187659. Epub 2010 Jul 8.
6
Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01.抗体 VRC01 广谱且强效中和 HIV-1 的结构基础。
Science. 2010 Aug 13;329(5993):811-7. doi: 10.1126/science.1192819. Epub 2010 Jul 8.
7
Anti-V3 monoclonal antibodies display broad neutralizing activities against multiple HIV-1 subtypes.抗 V3 单克隆抗体对多种 HIV-1 亚型表现出广泛的中和活性。
PLoS One. 2010 Apr 21;5(4):e10254. doi: 10.1371/journal.pone.0010254.
8
Structure of a clade C HIV-1 gp120 bound to CD4 and CD4-induced antibody reveals anti-CD4 polyreactivity.结构一个 clade C HIV-1 gp120 结合 CD4 和 CD4 诱导的抗体揭示抗 CD4 多反应性。
Nat Struct Mol Biol. 2010 May;17(5):608-13. doi: 10.1038/nsmb.1796. Epub 2010 Mar 31.
9
Anti-gp41 antibodies cloned from HIV-infected patients with broadly neutralizing serologic activity.从具有广泛中和血清学活性的 HIV 感染患者中克隆的抗 gp41 抗体。
J Virol. 2010 May;84(10):5032-42. doi: 10.1128/JVI.00154-10. Epub 2010 Mar 10.
10
The role of antibodies in HIV vaccines.抗体在 HIV 疫苗中的作用。
Annu Rev Immunol. 2010;28:413-44. doi: 10.1146/annurev-immunol-030409-101256.